The Cost-Utility of Magnetic Resonance Imaging for Breast Cancer in BRCA1 Mutation Carriers Aged 30–49
Recent evidence has investigated the costeffectiveness of magnetic resonance imaging (MRI) in younger women with a BRCA1 mutation. However, this evidence has not been contrasted with existing cost-effectiveness standards to determine whether screening is appropriate, given limited societal resourc...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Springer
2007
|
| Subjects: | |
| Online Access: | http://www.springer.com/economics/policy/journal/10198 http://hdl.handle.net/20.500.11937/8246 |
| Summary: | Recent evidence has investigated the costeffectiveness of magnetic resonance imaging (MRI) in younger women with a BRCA1 mutation. However, this evidence has not been contrasted with existing cost-effectiveness standards to determine whether screening is appropriate, given limited societal resources. We constructed a Markov model investigating surveillance tools (mammography, MRI, both in parallel) under a National Health Service (NHS) perspective. The key benefit of MRI is that increased sensitivity leads to early detection, and improved prognosis. For a 30- to 39-year-old cohort, the cost per quality-adjusted life year (QALY) of mammography relative to no screening was £5,200. The addition of MRI to this costs £13,486 per QALY. For a 40- to 49-year-old cohort, the corresponding values were £2,913 and £7,781. Probabilistic sensitivity analysis supported the cost-effectiveness of the parallel approach of mammography and MRI. It is necessary to extend this analysis beyond BRCA1 carriers within this age group, and also to other age groups. |
|---|